Blood disorder startup goes public by merging with embattled biotech


At three years old, an Atlas Venture spinout focused on blood disorders is going public by merging with another local biotech company.

Previous 'We're drowning': Employees, officials speak out in support of Inspira's plan to acquire Salem Medical Center
Next GUEST COMMENT: Family Scholar House CEO on adding up the economic costs of trauma